Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future
Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the r...
Main Authors: | Eva Rihackova, Michal Rihacek, Maria Vyskocilova, Dalibor Valik, Lubomir Elbl |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full |
Similar Items
-
Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients
by: Michal Rihacek, et al.
Published: (2022-06-01) -
Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice
by: Regina Demlova, et al.
Published: (2024-01-01) -
Immune Checkpoint Inhibitors—Associated Cardiotoxicity
by: Chenghui Li, et al.
Published: (2022-02-01) -
Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment
by: Filipe C. Marmelo, et al.
Published: (2019-02-01) -
Cardiotoxicity caused by gemcitabine
by: Yuri Isaakyan, et al.
Published: (2023-01-01)